Unicycive Therapeutics Inc (UNCY)

$UNCY mother fucker! I’m an idiot!

$UNCY on its way to a $5M market cap

$UNCY legitimate crooks

$UNCY OLC was not approved by the FDA due to manufacturing deficiencies - not related to the drug itself. UNCY is already in talks with a backup manufacturer. This has caused retail to pull back, along with the RS - not a great series of events. BUT Once the manufacturing is in place and OLC begins bringing in revenue - we should see a turnaround. Sucks right now, but I'm still bullish long term here.

$UNCY About to enter into the 3's today

$UNCY this company just needs to go bankrupt and put out of its misery. Gupta can have his second failed company under his belt

$UNCY #MATH #NASDAQ Metalpha Reports a Nearly Tripled Revenue & First Positive Annual Profit in FY2025! https://www.nasdaq.com/press-release/metalpha-reports-nearly-tripled-revenue-surge-first-positive-annual-profit-fy2025

$UNCY am I the only one tired of Corporate bio principals getting rich on the backs of investors? These CEO’s make millions while the company hasn’t shown a profit.

$UNCY 🤣🤣🤣🤣🤣 downward pressure still... The team at UNCY is relentless to bring this down as low as they can

$UNCY reconsider buying in the $2's as soon as this gives out

$UNCY here she goes

$UNCY Be prepared for a significant fall here

$UNCY RIP to all shareholders. This company just took your money and ran

$UNCY Type A meeting with FDA any time. Manufacturing issue was manufactured. FDA collect fees for every CRL letter or meeting.

$UNCY the company will be diluting this further. This stock is about to drop off a cliff today

$UNCY This is one ugly looking chart... my guess is we see that large institutions exited this most recent quarter... Keep in mind this company went from like 15 millions shares to over 130M in a year... LOL and still diluting to this day... I think they used to have like creating value for investors as one of their company foundations🤡🤡🤡

$UNCY Scam company. They are diluting all $50M from their ATM. They will not succeed as a company, since management is incompetent and constantly lie and dilute

$UNCY May seem like an absolute shyt-show but, we are up 5.22% percent over the past year. So there's SOME progress.

$UNCY buy 4.63 1.5k

Unicycive Therapeutics (Nasdaq: $UNCY) announced the publication of oxylanthanum carbonate (OLC) pivotal trial data in Clinical Journal of the American Society of Nephrology, noting that OLC was well-tolerated and enabled serum phosphate control in more than 90% of patients, as well as providing the benefit of low pill burden. This publication marks a milestone for the company as it continues to work with the FDA to address outstanding manufacturing questions and move toward bringing OLC to patients with chronic kidney disease who are on dialysis. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/unicycive. Among the highlights of today’s announcement are: -More than 90% of patients taking OLC achieved effective phosphate control. - Two-thirds of patients required three or fewer OLC tablets per day to achieve target serum phosphate levels, with most requiring no more than one tablet with each meal. - OLC was well tolerated in CKD patients on dialysis, with only 4% of patients discontinuing treatment due to treatment-related adverse events. - The most common treatment-related adverse events (all less than 10%) were gastrointestinal. See the full press release at https://ir.unicycive.com/news/detail/107/unicycive-therapeutics-announces-the-publication-of. Unicycive Therapeutics is a clinical-stage biotechnology company developing innovative therapies for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. Led by CEO Dr. Shalabh Gupta, MD and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/). Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer $MIST, $TNXP, $CDTX

Seekingalpha’s $UNCY column here! https://seekingalpha.com/article/4804194-unicycive-therapeutics-manageable-cmc-speed-bumppill-burden-edge-intact-buying